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Conclusions: The preablation BNP level is a strong predictor
of recurrent AF after RFCA of idiopathic AF. 
Perspective: Prior studies have demonstrated elevated BNP
levels in patients without structural heart disease who have
AF. Atrial mechanical dyssynchrony caused by AF could be
responsible for the elevation, and higher BNP levels might
reflect more advanced atrial remodeling. This may explain
why PVAI was less effective in patients with higher BNP
levels, and suggests that more extensive RFCA directed at
the atrial substrate might be appropriate when the BNP
level is elevated. 
Summary written by: Fred Morady, MD
Cardiovascular Surgery
Performance-Based Functional Assessment of
Patients Undergoing Transcatheter Aortic Valve
Implantation
Bagur R, Rodés-Cabau J, Dumont E, et al.
Am Heart J 2011;161:726-734.
Study Question: What is the impact of transcatheter aortic
valve implantation (TAVI) on functional status?
Methods: The authors assessed the Duke Activity Status
Index (DASI) as a measure of functional status pre-TAVI
and 6 months post-TAVI in 76 patients (80 ± 8 years old).
A 6-minute walk test was also performed in 46 patients at
baseline and 6 months. 
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Arrhythmias
Plasma B-Type Natriuretic Peptide Levels and
Recurrent Arrhythmia After Successful Ablation of
Lone Atrial Fibrillation
Hussein AA, Saliba WI, Martin DO, et al.
Circulation 2011;123:2077-2082.
Study Question: Do B-type natriuretic peptide (BNP) levels
predict recurrent atrial fibrillation (AF) after radiofrequency
catheter ablation (RFCA) of idiopathic AF? 
Methods: Pulmonary vein antral isolation (PVAI) was per-
formed by RFCA in 726 patients (mean age 57 years) with
idiopathic AF (paroxysmal in 78%). The plasma BNP level
was measured just prior to RFCA. Efficacy was determined
with serial clinic visits, event monitors, and 48-hour Holter
monitors. 
Results: The median BNP level was 52 pg/ml before RFCA.
The BNP level was higher in the 39% of patients who pre-
sented in AF than patients who presented in sinus rhythm.
The BNP level was not associated with recurrent AF during
the first 2 months post-ablation. During a median follow-up
of 26 months, 79% of patients remained arrhythmia-free.
The strongest independent predictor of recurrent AF was an
elevated BNP level (hazard ratio [HR], 2.3). The next
strongest were persistent AF (HR, 1.9), male gender (HR,
1.4), and presence of AF at the time of RFCA (HR, 1.3).
Increasing BNP quintiles were associated with progressively
higher AF recurrence rates.  
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recorded, of which 35 demonstrated a widened media. 
Conclusions: Clinical risk markers proposed in the 2010
ACC/AHA thoracic aortic disease guidelines and their
application as part of the ADD risk score comprise a highly
sensitive clinical tool for the detection of acute aortic dissec-
tion. 
Perspective: Given the relative infrequency of acute aortic dis-
section, which often leads to missed or delayed diagnosis,
application of the ADD risk score has the potential to draw
necessary clinical attention to the possibility of acute aortic
dissection while ensuring that >95% of patients with true
dissection undergo further investigation.
Summary written by: Debabrata Mukherjee, MD
Improvements in Exercise Performance After
Surgery for Ebstein Anomaly
Müller J, Kühn A, Vogt M, Schreiber C, Hess J, Hager A.
J Thorac Cardiovasc Surg 2011;141:1192-1195.
Study Question: Do exercise performance and quality-of-life
measures improve following surgical intervention for Ebstein
anomaly? 
Methods: This was a prospective study of 21 patients with
Ebstein anomaly undergoing primary (n = 14) or reoperation
(n = 7) for moderate to severe tricuspid regurgitation and, if
present, closure of an interatrial shunt. Patients were
assessed preoperatively and 6-18 months after surgery with a
cardiopulmonary exercise test and quality-of-life assessment
using the Medical Outcomes Study 36-item short form. 
Results: After surgery, peak oxygen uptake increased signifi-
cantly (68.4-77.3% predicted, p = 0.009) and ventilator
efficiency slope improved (32.5-29.3, p = 0.001). In the 14
primary operation patients, rest and peak exercise saturations
significantly improved (95-99%, p = 0.003 and 88-99%, p =
0.005, respectively) due to closure of interatrial shunts. At
baseline, patients overall reported good quality of life. The
only question that demonstrated improvement was regarding
health transition at follow-up. 
Conclusions: The assessment of myocardial viability did not
identify patients with a differential survival benefit from
CABG.
Perspective: The best time to intervene on patients with
Ebstein anomaly has not been well established. This study
demonstrates significant improvement in exercise capacity,
even with relatively preserved preoperative function and
quality of life. Therefore, earlier intervention prior to the
progression of right ventricular dysfunction may be a more
appropriate surgical management strategy for this diverse
and challenging patient population.
Summary written by: Jennifer C. Hirsch, MD
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Results: A significant increase in functional status was seen
with TAVI with mean DASI increasing from 10.3 ± 5.4 to
16.3 ± 8.3 at 6 months (p < 0.0001). The increase in DASI,
however, was not universal, with 30% of patients demon-
strating no increase or a decrease in DASI after TAVI. The
estimated glomerular filtration rate was an independent pre-
dictor of lack of improvement of DASI after TAVI (odds
ratio, 1.7; 95% confidence interval, 1.3-2.3). The mean dis-
tance walked in 6 minutes increased from 165 to 211 m at
follow-up. There was a good correlation between baseline
and final DASI and the 6-minute walk test results. 
Conclusions: TAVI is associated with an improvement in
functional status in most patients. 
Perspective: This study adds to the emerging data supporting
the survival and symptomatic benefit of TAVI in patients
with severe aortic stenosis. Baseline renal dysfunction
appears to be a predictor of acute kidney injury as well as of
failure of functional impairment in this population, and may
help identify patients who may be less likely to benefit from
this procedure.
Summary written by: Debabrata Mukherjee, MD
Sensitivity of the Aortic Dissection Detection Risk
Score, a Novel Guideline-Based Tool for
Identification of Acute Aortic Dissection at Initial
Presentation: Results From the International
Registry of Acute Aortic Dissection
Rogers AM, Hermann LK, Booher AM, et al., on behalf of the IRAD
Investigators.
Circulation 2011;123:2213-2218.
Study Question: What is the sensitivity of the high-risk clini-
cal features developed by the American Heart Association
(AHA) and American College of Cardiology (ACC) to
assist in early detection of acute aortic dissection? 
Methods: The investigators examined patients enrolled in the
International Registry of Acute Aortic Dissection (IRAD)
from 1996 to 2009. The number of patients with confirmed
acute aortic dissection who presented with 1 or more of 12
proposed clinical risk markers was determined. An aortic
dissection detection (ADD) risk score of 0-3 was calculated
based on number of risk categories (high-risk predisposing
conditions, pain features, examination features) in which
patients met criteria. 
Results: Of 2,538 patients with acute aortic dissection, 2,430
were identified by 1 or more of 12 proposed clinical risk
markers. With the ADD risk score, 108 patients were iden-
tified as low risk (ADD score 0), 927 patients intermediate
risk (ADD score 1), and 1,503 patients high risk (ADD
score 2 or 3). Among 108 patients with no clinical risk
markers present (ADD score 0), 72 had chest x-rays
9: Aortic valvuloplasty is indicated in children with isolated
valvar aortic stenosis who have a resting peak systolic valve
gradient (by catheter) of ≥50 mm Hg. 
10: Transcatheter patent ductus arteriosus (PDA) occlusion is
indicated for the treatment of a moderate-sized or large PDA
with left-to-right shunt that results in any of the following:
congestive heart failure, failure to thrive, pulmonary overcircu-
lation, or an enlarged left atrium or left ventricle, provided
anatomy and patient size are suitable.
Summary written by: Debabrata Mukherjee, MD
General Cardiology
Anticoagulant Options – Why the FDA Approved a
Higher but Not a Lower Dose of Dabigatran
Beasley BN, Unger EF, Temple R.
N Engl J Med 2011;364:1788-1790.
Conclusions: The following are 10 points to remember about
anticoagulant options: 
1: In this article, the Food and Drug Administration (FDA)
explains why it approved the 150 mg twice daily dosing of
dabigatran for atrial fibrillation, but not the lower dose of
110 mg twice daily. Many believe that both doses should
have been approved, with the dose decision left to patients
and physicians based on the available evidence and individ-
ual concerns and needs. 
2: Dabigatran is a novel anticoagulant FDA approved as an
alternative to warfarin for reduction of stroke risk and sys-
temic embolism in patients with nonvalvular atrial
fibrillation. 
3: Approval was based on RE-LY, a multicenter, active-
control, noninferiority trial, in which patients were
randomly assigned to receive twice daily 150 or 110 mg of
dabigatran, or warfarin. Warfarin was titrated to achieve an
international normalized ratio of 2.0-3.0. Both dabigatran
regimens were noninferior to warfarin, but the 150 mg regi-
men was significantly superior to warfarin and to the 110
mg regimen. 
4: Re major bleeding, 110 mg of dabigatran was superior to
warfarin, whereas 150 mg was similar to warfarin. Thus, 150
mg reduced the risk of stroke and systemic embolism greater
than the 110 mg dose, but with the risk of greater bleeding. 
5: The FDA acknowledges that in patients with reason for
heightened concern about bleeding, the lower dose might
have seemed desirable, even at the cost of increased risk of
stroke. 
6: To determine whether there was evidence for a benefit/risk
of the dabigatran doses based on incremental risk of bleeding
Congenital Heart Disease
Indications for Cardiac Catheterization and
Intervention in Pediatric Cardiac Disease:
A Scientific Statement From the American Heart
Association
Feltes TF, Bacha E, Beekman RH 3rd, et al., on behalf of the
American Heart Association Congenital Cardiac Defects
Committee of the Council on Cardiovascular Disease in the
Young, Council on Clinical Cardiology, and Council on
Cardiovascular Radiology and Intervention.
Circulation 2011;May 2:[Epub ahead of print].
Perspective: The following are 10 points to remember about
this Scientific Statement from the American Heart
Association: 
1: Complete cardiac echocardiographic imaging or alterna-
tive noninvasive imaging modes such as magnetic resonance
imaging or computed tomography are indicated before inva-
sive cardiac catheterization to facilitate planning of data
collection and performance of an intervention. 
2: Cardiac catheterization is recommended to assess pul-
monary resistance and reversibility of pulmonary hypertension
in patients with congenital heart disease or primary pul-
monary hypertension when accurate assessment of pulmonary
resistance is needed. 
3: Cardiac catheterization is indicated in patients being
assessed for cardiac transplantation unless the patient’s risk
for catheterization outweighs the potential benefit. 
4: Transseptal puncture is indicated for any patient for whom
a transcatheter intervention is optimally performed from a left
atrial approach and in whom no interatrial communication
exists. 
5: Atrial septostomy is indicated to enhance atrial mixing or
to decompress the left atrium. 
6: Transcatheter secundum atrial septal defect (ASD) closure
is indicated in patients with hemodynamically significant
ASD with suitable anatomic features and contraindicated with
a secundum ASD and advanced pulmonary vascular obstruc-
tive disease. 
7: It is reasonable for infants who weigh ≥5 kg, children, and
adolescents with hemodynamically significant muscular ven-
tricular septal defect (VSD) to undergo percutaneous VSD
device closure.  
8: Pulmonary valvuloplasty is indicated for a patient with criti-
cal valvular pulmonary stenosis, valvar pulmonic stenosis, and
a peak-to-peak catheter gradient or echocardiographic peak
instantaneous gradient of ≥40 mm Hg or clinically significant
pulmonary valvar obstruction in the presence of right
ventricular dysfunction. 
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or stroke, the FDA conducted a subset analysis. The focus
was on elderly patients, and patients with impaired renal
function and previous bleeding episodes. 
7: Among the 40% of patients in the RE-LY trial who were
75 years of age or older, the rate of stroke or systemic
embolism was lower with 150 mg (1.4 per 100 patient-
years) than 110 mg (1.9 per 100 patient-years), but the rate
of major bleeding was higher (5.1 vs. 4.4 per 100 patient-
years). A benefit–risk assessment in which strokes and
systemic emboli are given more weight than nonfatal bleed-
ing events would find the higher dose more favorable in the
elderly. 
8: In patients with moderate renal impairment, the rate of
stroke or systemic embolism with 150 mg of dabigatran was
approximately half that with 110 mg, and the rate of bleed-
ing was no greater. 
9: To assess whether there is an incremental bleeding risk,
they analyzed the risk of re-bleeding in the 57% of patients
who had a major bleeding event during the study, who
either resumed taking or had no interruption in their study
medication at the same dose. The percentages of patients
who had an additional major hemorrhage were similar in all
groups. 
10: The Cardiovascular and Renal Drugs Advisory
Committee considered each issue at length and slightly
favored approval of only the higher strength. However, the
FDA leadership's final decision was that using the low dose
as a ‘play it safe’ option for patients and physicians repre-
sented an undesirable stimulus to use a less-effective
regimen, and would lead to unnecessary strokes and disabil-
ity.
Perspective: While the FDA leadership explanation for its
decision is clear, many would argue it is not adequate, and
the decision should not be in their purview and the process
sets an undesirable precedent. 
Summary written by: Melvyn Rubenfire, MD
Growth-Differentiation Factor-15 Is a Robust,
Independent Predictor of 11-Year Mortality Risk in
Community-Dwelling Older Adults: The Rancho
Bernardo Study
Daniels LB, Clopton P, Laughlin GA, et al.
Circulation 2011;123:2101-2110.
Study Question: Are elevated plasma levels of growth-differenti-
ation factor-15 (GDF-15) predictive of mortality in subjects
without a known history of cardiovascular disease (CVD)? 
Methods: Plasma levels of GDF-15, N-terminal pro-B-type
natriuretic peptide (NT-proBNP), and C-reactive protein
(CRP) were measured in 1,391 Rancho Bernardo Study
participants, mean age 70 years, with no history of CVD.
Follow-up was 11 years. 
Results: GDF-15 was an independent predictor of all-cause,
CV, and non-CV mortality, and was a stronger predictor of
all-cause mortality than either NT-proBNP or CRP (hazard
ratio [HR] per standard deviation log10 units, 1.5; p < 0.0001
for GDF-15 vs. 1.3, p < 0.0001 for NT-proBNP; CRP was
not a significant predictor). Only GDF-15 predicted non-
CV death (HR, 1.6; p < 0.0001). GDF-15 improved
discrimination and reclassification for all-cause and non-CV
mortality with borderline improvement for CV mortality;
NT-proBNP significantly improved reclassification for all-
cause and CV mortality; CRP did not improve
reclassification for any endpoint. Participants in the highest
quartile of both GDF-15 and NT-proBNP had an increased
risk of death compared with only NT-proBNP elevated
(HR, 1.5; p = 0.01). 
Conclusions: GDF-15 is a strong predictor of all-cause, CV,
and non-CV mortality in community-dwelling older individ-
uals. 
Perspective: The current study expands the potential useful-
ness of this informative biomarker (GDF-15)  by
demonstrating its independent predictive value for mortality
in subjects with no previous history of CVD. Further studies
are necessary to confirm these findings in other cohorts, as
well as to test possible therapeutic and lifestyle interventions
in patients with elevated GDF-15 levels.
Summary written by: Daniel T. Eitzman, MD
Prevalence of C-Reactive Protein Elevation and
Time Course of Normalization in Acute Pericarditis:
Implications for the Diagnosis, Therapy, and
Prognosis of Pericarditis
Imazio M, Brucato A, Maestroni S, et al.
Circulation 2011;123:1092-1097.
Study Question: What is the frequency of high-sensitivity C-
reactive protein (hs-CRP) elevation in patients with acute
pericarditis; its time course of normalization; and the possi-
ble importance for diagnosis, therapy, and prognosis? 
Methods: Two hundred consecutive patients with viral or
idiopathic acute pericarditis (mean age, 53 ± 15.5 years; 103
men) were studied from August 2005 to August 2007 in two
Italian referral centers. Hs-CRP was determined at presenta-
tion and then every week until normalization. Time-to-event
distributions were estimated by the Kaplan-Meier method
and compared with the log-rank test. The Cox proportional
hazards model was used to identify independent risk factors
for recurrences. 
Results: Hs-CRP elevation was recorded in 78% at presenta-
tion. Recognized causes of a negative hs-CRP at
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placebo, D-dimer concentrations were reduced in all dabiga-
tran dose groups by an average of 37% and 45% at weeks 1
and 4, respectively (p < 0.001). Fourteen (3.8%) patients
died, had a myocardial infarction, or had a stroke in the
placebo group, compared with 17 (4.6%) in the 50 mg, 18
(4.9%) in the 75 mg, 12 (3.0%) in the 110 mg, and 12
(3.5%) in the 150 mg dabigatran groups.
Conclusions: Dabigatran, in addition to dual antiplatelet ther-
apy, was associated with a dose-dependent increase in bleeding
events and significantly reduced coagulation activity in patients
with a recent myocardial infarction. 
Perspective: In this study, dabigatran significantly reduced
coagulation activity and may have the potential to reduce
cardiovascular events when added to dual antiplatelet treat-
ment, but in general, novel anticoagulants added to double
antiplatelet therapy have shown marginal or no benefit at
the cost of increased bleeding. The net clinical benefit of
dabigatran, balancing the reduction of thromboembolic
events versus the increased risk of bleeding, can only be
appropriately evaluated in a large-scale, adequately powered
phase III study. 
Summary written by: Debabrata Mukherjee, MD
Heart Failure/Transplant
Transcriptomic Biomarkers for the Accurate
Diagnosis of Myocarditis
Heidecker B, Kittleson MM, Kasper EK, et al.
Circulation 2011;123:1174-1184.
Study Question: Does the transcriptome obtained from an
endomyocardial biopsy yield clinically relevant and accurate
molecular signatures for diagnosis of lymphocytic
myocarditis? 
Methods: Microarray analysis was performed on samples from
patients with histologically proven lymphocytic myocarditis (n
= 16) and idiopathic dilated cardiomyopathy (n = 32) to
develop accurate diagnostic transcriptome-based biomarkers
using multiple classification algorithms. Validation with real-
time reverse-transcription polymerase chain reaction
(RT-PCR) was performed in a randomly selected subset of
patients. 
Results: The investigators identified 9,878 differentially
expressed genes in lymphocytic myocarditis versus idiopathic
dilated cardiomyopathy from which a transcriptome-based
biomarker containing 62 genes was identified that distin-
guished myocarditis with 100% sensitivity (95% confidence
interval, 46-100) and 100% specificity (95% confidence
interval, 66-100), and was generalizable to a broad range of
secondary cardiomyopathies associated with inflammation
(n = 27), ischemic cardiomyopathy (n = 8), and the normal
heart  (n = 11).
presentation were early assessment in 34% and previous
anti-inflammatory therapies in 50%. Hs-CRP normaliza-
tion was achieved with 60% at week 1, 85% at week 2, 95%
at week 3, and all cases at week 4. In multivariable analysis,
incomplete response to empirical anti-inflammatory therapy
at week 1 (hazard ratio [HR], 2.98; p < 0.001), corticos-
teroid therapy (HR, 2.80; p < 0.001), and the presence of
elevated hs-CRP at week 1 (HR, 2.36; p = 0.004) were
independent risk factors for recurrence.  
Conclusions: Hs-CRP is elevated at the initial presentation in
three of four cases of acute pericarditis, identifies patients at
higher risk of recurrence, and could be used to monitor disease
activity and select appropriate therapy length. 
Perspective: These study results suggest that a diagnosis of
pericarditis should rely on clinical criteria and not only on
hs-CRP elevation, although it may support the clinical sus-
picion. The study further suggests that persistently elevated
hs-CRP may identify patients at higher risk of recurrence,
and for patients with elevated hs-CRP, anti-inflammatory
therapy should be continued until hs-CRP normalization
instead of an empirical length of therapy.
Summary written by: Debabrata Mukherjee, MD
Dabigatran vs. Placebo in Patients With Acute
Coronary Syndromes on Dual Antiplatelet Therapy:
A Randomized, Double-Blind, Phase II Trial
Oldgren J, Budaj A, Granger CB, et al., on behalf of the
RE-DEEM Investigators.
Eur Heart J 2011;May 7:[Epub ahead of print]. 
Study Question: What are the safety and indicators of efficacy
of the novel oral direct thrombin inhibitor, dabigatran, after
an acute coronary syndrome?
Methods: In RE-DEEM, a double-blind, placebo-controlled,
dose-escalation trial, 1,861 patients (99.2% on dual
antiplatelet treatment) in 161 centers were enrolled at a
mean 7.5 days after an ST-elevation (60%) or non-ST-
elevation (40%) myocardial infarction and randomized to
twice daily treatment with dabigatran 50 mg (n = 369), 75
mg (n = 368), 110 mg (n = 406), 150 mg (n = 347), or
placebo (n = 371). Primary outcome was the composite of
major or clinically relevant minor bleeding during the 6-
month treatment period. The proportion of patients
experiencing the primary outcome, major or clinically rele-
vant minor bleeding per-treatment group, was analyzed by
the Cochran–Armitage linear trend test.
Results: There were 96 primary outcome events and, com-
pared with placebo, a dose-dependent increase with
dabigatran (hazard ratio [HR] 1.77, 95% confidence inter-
val [CI] 0.70-4.50 for 50 mg; HR 2.17, 95% CI 0.88-5.31
for 75 mg; HR 3.92, 95% CI 1.72-8.95 for 110 mg; and
HR 4.27, CI 1.86-9.81 for 150 mg). Compared with
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Multiple classification algorithms and quantitative RT-PCR
analysis further reduced this subset to a highly robust molecu-
lar signature of 13 genes, which still performed with 100%
accuracy. 
Conclusions: Transcriptomic biomarkers from a single endomy-
ocardial biopsy can improve the clinical detection of patients
with inflammatory diseases of the heart. 
Perspective: This study suggests that both the transcriptomic
biomarker and the parsimonious molecular signature per-
formed highly accurately and should be clinically valuable
tools for the detection of myocarditis. Although the more
comprehensive biomarker of 62 genes performed with
slightly higher accuracy, the 13-gene molecular signature is
more practical for clinical application. 
Summary written by: Debabrata Mukherjee, MD
Interventional Cardiology
Coronary Revascularization Trends in the United
States, 2001-2008
Epstein AJ, Polsky D, Yang F, Yang L, Groeneveld PW.
JAMA 2011:305;17:1769-1776.
Study Question: What are the national trends in the rates and
type of coronary revascularization procedures in the United
States over a decade? 
Methods: This was an examination of administrative databases,
primarily the Nationwide Inpatient Sample (NIS), between
2001 and 2008. This data set was examined for procedure
codes identifying percutaneous coronary intervention (PCI)
with or without drug-eluting stents (DES) and coronary
artery bypass grafting (CABG). The NIS is a 20% stratified
random sample of US hospitals, and the procedure rate for US
adults was extrapolated from this sample. Known previous
work has suggested that 6-18% of PCIs are outpatient.
Because the NIS primarily reflects inpatient discharge data, to
include this outpatient group, Medicare data from the Centers
for Medicare and Medicaid Services procedure claims were
used. 
Results: The annual US rate of coronary revascularization
decreased by 15% from 2001 to 2008. There was a 38%
reduction in annual CABG volume (p < 0.001), but no sig-
nificant difference in PCI rate (p = 0.74). This projection
suggested ~130,000 fewer CABG procedures in 2008 com-
pared to 2001, but an increase in hospitals providing CABG,
from 212 to 241 (p = 0.03). There was a 26% increase in hos-
pitals providing PCI (246 vs. 331, p < 0.01). Overall, this
provided a 28% decrease in the median case load per hospital
for CABG, and a substantial increase in the number of hos-
pitals providing fewer than 100 CABG procedures per year
(23 vs. 62, p < 0.01). The use of DES dramatically increased
from 2001 to 2005, at which point 90% of all PCI procedures
used DES. However, thereafter, the volume subsequently
decreased such that by 2008, DES were used in 68% of pro-
cedures.
Conclusions: CABG procedural volume has markedly decreased
within a decade, but PCIs remain unchanged. Initial dramatic
enthusiasm for DES has been tempered over time. 
Perspective: This study confirms the slow erosion of CABG
volume. Maintenance of stability of PCI has likely been at
the expense of CABG volume. I believe the most important
findings in this study are the rapid increase in DES use
despite inadequate data in patients undergoing PCI, and the
decrease in volume of total coronary revascularization proce-
dures over the last decade. Whether this means that medical
therapy has improved despite an increase in comorbidities
remains to be further elucidated.
Summary written by: Himanshu J. Patel, MD
Patterns and Intensity of Medical Therapy in
Patients Undergoing Percutaneous Coronary
Intervention
Borden WB, Redberg RF, Mushlin AI, et al.
JAMA 2011;305:1882-1889.
Study Question: How useful is optimal medical therapy
(OMT) in patients undergoing percutaneous coronary inter-
vention (PCI) for stable coronary artery disease (CAD), and
how was it impacted by the COURAGE trial? 
Methods: The authors assessed the use of OMT before and
after PCI in patients with stable CAD undergoing PCI in the
NCDR® (National Cardiovascular Data Registry) between
September 1, 2005, and June 30, 2009. They compared the
use of OMT before and after publication of the COURAGE
trial. OMT was defined as either being prescribed or having a
documented contraindication to all medicines (antiplatelet
agent, beta-blocker, and statin). 
Results: The study cohort was comprised of 467,211 patients,
of whom 37.1% underwent PCI before and 62.9% after publi-
cation of the COURAGE trial. OMT was used in 44% of
patients before PCI, and 65% of patients received it at dis-
charge. There was only a slight change in use of OMT prior
to PCI after the COURAGE trial (43.5% prior and 44.7%
after COURAGE). The use of OMT after PCI increased
from 63.5% to 66% following publication of the COURAGE
trial. 
Conclusions: OMT is markedly underutilized in patients with
stable CAD. 
Perspective: This study demonstrates an immense gap in
quality of care of patients with stable CAD. The underuse
of OMT in such a large number of patients before and after
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PCI is concerning and invokes the need for dedicated qual-
ity improvement efforts to optimize the use of appropriate
medical therapy.
Summary written by: Debabrata Mukherjee, MD
Prevention/Vascular
Physical Activity Advice Only or Structured
Exercise Training and Association With HbA1c
Levels in Type 2 Diabetes: A Systematic Review
and Meta-Analysis
Umpierre D, Riberio PA, Kramer CK, et al.
JAMA 2011;305:1790-1799.
Study Question: Is there an additional value of a structured
exercise training program compared to physical activity
advice with or without dietary interventions on change in
glycated hemoglobin (HbA1c) in type 2 diabetics? 
Methods: The authors conducted a systematic review and
meta-analysis of published randomized controlled clinical tri-
als (RCTs) of at least 12 weeks’ duration designed to assess
the utility of exercise interventions with or without dietary
co-intervention on HbA1c in type 2 diabetics. Databases were
searched from January 1980 through February 2011. Of
4,191 articles retrieved, 47 RCTs (8,538 patients) were
included. 
Results: Mean age ranged from 52 to 67 years. Study dura-
tion ranged from 12 to 52 weeks. The majority of programs
recommended three sessions per week. Adherence rate was
>75% in 14 of the 15 structured exercise studies. Dropout
rate was <20% in 90% of all 47 RCTs. Overall, structured
exercise training was associated with a decline in HbA1c
level (−0.67%) compared with control participants. In addi-
tion, structured aerobic exercise (−0.73%), structured
resistance training (−0.57%), and both combined (−0.51%)
were each associated with declines in HbA1c levels.
Structured exercise durations of more than 150 minutes per
week were associated with HbA1c reductions of 0.89% ver-
sus 0.36% with 150 minutes or less. Overall, interventions
of physical activity advice were associated with lower HbA1c
levels (−0.43%). Combined physical activity and dietary
advice was associated with decreased HbA1c (−0.58%).
Physical activity advice alone was not associated with
HbA1c changes. 
Conclusions: Structured exercise training that consists of aerobic
exercise, resistance training, or both is associated with HbA1c
reduction in patients with type 2 diabetes. Structured exercise
training of more than 150 minutes per week is associated with
greater HbA1c declines. Physical activity advice is associated
with lower HbA1c only when combined with dietary advice. 
Perspective: The challenge is to find ways to provide struc-
tured lifestyle interventions cost-effectively and how to
improve adherence. Use of cardiac rehab facilities, equip-
ment, and personnel would seem logical. The message that
more is better and structured exercise is necessary to impact
glycemic control is not surprising since compliance with
physical activity advice without coaching and accurate moni-
toring of adherence is usually unsuccessful.
Summary written by: Melvyn Rubenfire, MD
Triglyceride-Rich Lipoproteins and High-Density
Lipoprotein Cholesterol in Patients at High Risk of
Cardiovascular Disease: Evidence and Guidance
for Management
Chapman MJ, Ginsberg HN, Amarenco P, et al.
Eur Heart J 2011;Apr 29:[Epub ahead of print].
Perspective: The following are 10 points to remember from
the European Atherosclerosis Society Consensus Panel rec-
ommendations: 
1: Optimal treatment including lifestyle intervention and
pharmacotherapy aimed at lowering plasma concentrations
of low-density lipoprotein cholesterol (LDL-C), reducing
blood pressure, and preventing thrombotic events fails to
‘normalize’ risk in people at high risk of cardiovascular dis-
ease (CVD). 
2: Post-hoc analyses of prospective trials in acute coronary
syndrome and stable coronary heart disease reveal that ele-
vated plasma levels of triglycerides and low plasma
concentrations of high-density lipoprotein cholesterol (HDL-
C) are associated with a high risk, even at or below
recommended LDL-C goals. 
3: There is convincing evidence that elevated levels of
triglyceride-rich lipoproteins (TRLs) and their remnants
(chylomicron-R and VLDL-R) and low levels of HDL-C
are cardiovascular risk factors that require therapeutic strate-
gies for management. 
4: The functioning characteristic of circulating HDL particles
in the healthy state includes reverse cholesterol transport, and
anti-oxidative, anti-inflammatory, vasodilatory, and
antithrombotic properties. 
5: Lifestyle interventions influence the metabolism of HDL
and TRL remnants as well as insulin resistance. Smoking
increases TRL remnants and decreases HDL-C levels,
which are reversed on quitting. Aerobic exercise causes
long-lasting reduction in triglycerides by up to 20%, and
increases in HDL-C by up to 10%. 
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6: Evidence is supportive of therapeutic approaches aimed at
concomitantly lowering TRL and raising HDL-C to reduce
CV risk. Of these options, niacin, fibrates, and marine sources
of omega-3 polyunsaturated fatty acids influence   levels of
multiple lipids and lipoproteins and, therefore, clinically bene-
ficial effects observed cannot be ascribed solely to changes in
any single lipoprotein fraction. 
7: Niacin in combination with a statin has been shown to
reduce progression of carotid and coronary disease even in
patients without the atherogenic phenotype and despite a
low LDL-C level. Its effects include up to a 30% increase in
HDL-C, modest lowering of LDL-C and triglycerides, and
several anti-atherosclerotic and antithrombotic properties. 
8: Results from individual fibrate monotherapy outcomes tri-
als in nondiabetics and a major trial in diabetes have been
variable, and primarily indicate a reduction in nonfatal
myocardial infarction and revascularization, but with no
effect on stroke or CV death. 
9: In summary, statins firmly remain the first-line treatment
of choice for attainment of LDL-C goal in patients at high
risk of CVD. After LDL-C goal attainment, however, and if
triglyceride levels remain elevated (≥150 mg/dl) and HDL-C
low (<40 mg/dl) despite intensive lifestyle intervention, the
addition of fibrate or niacin may be considered. 
10: The European Guidelines desirable lipid level in patients
at high risk of CVD includes: LDL-C <100 mg/dl and <80
mg/dl in very high risk, triglycerides <150 mg/dl, HDL-C
>40 mg/dl in men and >45 mg/dl in women, and non-
HDL-C <100 mg/dl.
Summary written by: Melvyn Rubenfire, MD
Effects of Low-Dose, Controlled-Release,
Phentermine Plus Topiramate Combination on
Weight and Associated Comorbidities in
Overweight and Obese Adults (CONQUER): A
Randomised, Placebo-Controlled, Phase 3 Trial
Gadde KM, Allison DB, Ryan DH, et al.
Lancet 2011;377:1341-1352.
Study Question: What is the efficacy and safety of two doses of
phentermine plus topiramate controlled-release combination
as an adjunct to diet and lifestyle modification for weight
loss and metabolic risk reduction in individuals who are
overweight and obese, with two or more risk factors? 
Methods: The CONQUER trial is a 56-week phase 3 placebo-
controlled trial that randomly assigned overweight or obese
adults (ages 18-70 years), with a body mass index (BMI) of
27-45 kg/m2 and two or more comorbidities (hypertension,
dyslipidemia, diabetes or prediabetes, or abdominal obesity) to
placebo, once-daily phentermine 7.5 mg plus topiramate 46
mg (low dose), or once-daily phentermine 15 mg plus topi-
ramate 92 mg (high dose) in a 2:1:2 ratio in 93 US centers.
Randomized patients were stratified by sex and diabetic sta-
tus. Primary endpoints were the percentage change in
bodyweight and the proportion of patients achieving at least
5% weight loss. Analysis was by intention to treat.
Results: Data were available on 2,448 patients; 70% were
women and 86% were white. Mean age was 51.1 years,
weight 103.1 kg, and BMI 36.6 kg/m2. At 56 weeks,
change in bodyweight was –1.4 kg, –8.1 kg, and –10.2 kg
in the patients assigned to placebo, low dose, and high
dose, respectively. Twenty-one percent of the patients
achieved at least 5% weight loss with placebo; 62% (p <
0.0001) with low dose; and 70% (p < 0.0001) with high
dose. For ≥10% weight loss, the corresponding numbers
were 7%, 37%, and 48%. The most common side effects in
active drug groups were dry mouth and paresthesias (21%
in each), and constipation (17%), insomnia (10%), dizzi-
ness (10%), and dysgeusia (10%; all with high dose). Four
percent of patients with placebo, 4% with low dose, and
7% with high dose had depression-related adverse events;
and 3%, 5%, and 8%, respectively, had anxiety-related
adverse events. Significant improvements were noted in
blood pressure, waist circumference, concentrations of
lipids, glycemia, and high-sensitivity C-reactive protein
and adiponectin with phentermine plus topiramate com-
pared with placebo. 
Conclusions: The combination of phentermine and topiramate,
with office-based lifestyle interventions, might be a valuable
treatment for obesity that can be provided by primary care
physicians. 
Perspective: Phentermine is a safe anorexigen, and topiramate
is an anticonvulsant used in children and adults for seizures
and migraine. The magnitude of weight loss and improve-
ment in coronary risk factors and risk markers with both the
low- and high-dose combination is at least as great as any of
the other weight loss agents available and in published clini-
cal trials. I am hopeful that this agent will be available soon.
Summary written by: Melvyn Rubenfire, MD
These journal article summaries were extracted from
Cardiosource, your source for the best in cardiovascular
information and education. www.cardiosource.org
100 Eagle, Cannon
Scanning the Literature
JACC Vol. 58, No. 2, 2011
July 5, 2011:93-100
